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The  remarkable  development  and  application  of  new  genetic 
technologies over the past decades has been accompanied by profound changes 
in the way in which research is commercialized in the life sciences. As results, 
new varieties of commercially grown crops with improved or new traits are 
developed. Many thousands of patents which assert rights over DNA sequences 
have been granted to researchers across the public and private sector. The effects of 
many of these patents are extensive, because inventors who assert rights over DNA 
sequences obtain protection on all uses of the sequences. Extremely valuable to 196                                                                                   GENETIKA, Vol. 42, No. 1,195 -208, 2010 
breeders in the national agricultural research system is the ability to genotype 
their collections to get a clear picture of their diversity and how diversity could 
be enhanced through sharing and access to global collections. The issue of the 
eligibility for patenting of DNA sequences needs to be reopened. Patents that 
assert rights over DNA sequences and their uses are, in some cases, supportable, 
but  in  others,  should  be  treated  with  great  caution.  Rights  over  DNA 
sequences  as  research  tools  should  be  discouraged.  That  the  best  way  to 
discourage the award of such patents is by stringent application of the criteria 
for patenting, particularly utility. A more equitable, ethically – based food 
and agricultural system must incorporate concern for three accepted global 
goals: improved well being, protection of the environment and improved 
public health (particular point food from GMO). To mitigate conflict one of 
the approach to solve problem is ethical and truthful label of GM food, 
because  consumers  have  a  right  to  choose  whether  to  eat  genetically 
modified foods or not. Interesting examples and risks as consequences of free 
availability of genetic resources utilization, its transformation, patenting of   “new” 
organism and selling it back to the genetic resource owner are presented.  Society   
has obligations to raise levels of   nutrition and standards living by all respect to 
ethics at each step. 
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INTRODUCTION 
Over the past two  or  more decades, the structure  of agricultural  input  has 
changed very rapidly - input of private sector in agriculture and food  Research and 
Development  (R&D)  has  grown  dramatically,  while  public-sector  investment  has 
remained  relatively  constant  (SHOEMAKER  et  al.,  2001).  The  use  of  intellectual 
property (IP),  in the form of  plant variety protection certificates and utility patent   has  
also expanded very rapidly over roughly the same time period. More than any other 
component of agricultural R&D, agricultural biotechnology exemplifies these trends 
(J.E.M. 2001). Patenting in a specific type of plant biotechnology - plant cultivars is also 
of  interest. Patents for cultivars are now issued whether or not they result from the use 
of some molecular technique such as gene insertion.  
Private  firms almost completely  dominate  cultivar  patenting.  United  States 
private firms are patenting far more cultivars than do non -US firms. Two crops, maize 
and  soybeans,  also  account  for  most  of  the  US  utility  patents  on  plant  cultivars. 
Patents  represent  in  Europe  only  a  minor  mechanism  for  technology  transfer, 
access  to  information  (publications)  and  various  forms  of  capacity  and  institution 
building  and are important mechanisms to transfer technologies and facilitate their use 
(ECE, 1995). Few patents are relevant in potato breeding, where the private keep new 
varieties  available  for  further  breeding  and  claims  not  to  seek  profit  from  poor 
farmers in developing countries. Clearly, both governmental institutions, universities 
and private firms devote a substantial proportion of program patenting in agricultural 
biotechnology  to  patents that, concern biological control  of pests and  diseases for 
plants and animals. Intellectual property issues were and are some of the most K. KONSTANTINOV et al.: ETHICS IN SCIENTIFIC RESULTS APPLICATION                            197 
controversial in modern biotechnology (OTA, 1989; LESSER, 1991). In this report the 
short  overview  on  contemporary  research  in  the  field  of  plant  biotechnology  and 
protecting obtained results in the form of patent  
 
BIOTECHNOLOGY 
The  agricultural  commons  were  created  and  nurtured  by  countless 
generations of breeders and seed-savers without commercial reward, and were 
bequeathed to mankind at no cost. The ancient practice of farmers and gardeners 
saving seed from their harvest for planting next season is an inalienable right. 
Seed saving  is essential to adapting plants to local conditions, especially where 
environmental degradation and global climate change processes occur.  Seed must 
not become a product that can be dealt only to breeding new varieties.   
Agricultural biotechnology may be understood as these of organisms or 
parts of an organism to make or improve products or processes in agriculture. The 
domestication  of  plant  species  and  selection  of  desired  characteristics  within 
agricultural  species  would  qualify  under  this  definition.  What  biotechnology 
represents  today  is  new  knowledge  about  the  natural  processes  of  the  DNA 
replication,  breakage,  ligation,  and  repair  that  has  made  possible  a  deeper 
understanding of the mechanics of cell biology and the hereditary process itself 
(MC COUCH, 2001; KONSTANTINOV et al., 1993; MLADENOVIĆ DRINIĆ et al., 2002).  
Although in agriculture the term biotechnology has been most closely associated 
with genetic manipulation at the DNA level, or genetic engineering, it may refer 
to a variety of techniques or products. These may include, for example, use of 
molecular  markers  in  genetic  improvement  or  more  general  use  of  genomic 
information (SMITH et al., 1987; MLADENOVIĆ DRINIĆ et al., 2004). Similarly, the 
use of enzymes for fermentation in brewing or cheese making would be early 
examples of a broadly defined food biotechnology. Genetically engineering yeast 
to modify or improve a baking process would be an example of a narrower or 
more recent definition of food biotechnology.  
The benefits that are hoped for from the biotechnology based on genetic 
engineering include: (i) increased productivity of crops, growth rates and ratio of 
plant  product  which  could  be  used;  (ii)  increased  quality  of  crops,  including 
nutritional  quality  and  storage  properties;  (iii)  adaptation  of  plants  to  specific 
environmental conditions; (iv) broaden plants tolerance to stress; (v) production of 
substances in food crops and (vi) utilization of new raw materials.  Ecological and 
scientific studies to produce better crops and farming practices should lie at the 
heart of biotechnology. Future potential of genetic engineering to produce more 
nutritious and safer food than we consume now, by the breeding of new varieties of 
crops excluding the naturally occurring  toxins and carcinogens that we consume 
everyday from the food.   
Some transgenic crops still contain antibiotic resistance genes when they 
are grown (MLADENOVIĆ et al., 1991; MARTINCAN et al., 1994; KONSTANTINOV et al., 
1993.,  KONSTANTINOV  et  al.,  1997;  KONONOV  et  al.,  1997).This  concern  lead  to 
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corn borer, that was being marketed  by Ciba-Geigy (COGHLAN, 1996). Studies in 
mice  and  rats  of  the  protein  product  of  the  marker  NPTII  gene  which  control 
neomycin resistance found it as safe for consumption (FUCHS et al., 1993). Therefore 
particular  variety  of  soybeans  would  have  had  to  be  labeled  under  FDA  policy. 
However it has been decided to abandon development of this variety (NESTLE, 1996).  
The major concerns are ecological and have been the subject of a number 
of studies and reports (OTA, 1988, 1991; RUDELSHEIM et al., 1994). The issue has, 
and continues need to be addressed by scientific studies. Prospective effect has been 
partially  controlled  by  the  Convention  on  Biological  Diversity,  which  regulates 
collecting  of  species  after  1993  in  the  wild.  It  does  not  regulate  the  use  of  the 
samples from botanical gardens that were collected before this, and also it does not 
regulate the resources found in the oceans of international waters (TANGLEY, 1996). 
It covers the country of ownership, but inside countries there are also disputed claims 
to which community has rights. This new approach contrasts with the practice which 
still continues among many researchers for free exchange of materials, and there are 
unresolved  ethical  questions  about  whether  one  country  or  group  can  claim 
ownership of a species. Another approach would be to see them as the common 
heritage of all species and all humanity. 
GRAFF et al. (2002, 2003a, b) offer definition of agricultural biotechnology 
broader  and  it  includes  such  areas  as  crop  resources  that  may  not  have  been 
developed using the techniques of molecular biology. They defined different kinds of 
technologies:  resources  transformation  platforms  and  traits,  and  found  that  some 
institutions tended to combine different types of technology, dependent on the type 
of  firm.  On  the  research  input  side,  data  on  investment  in  the  agricultural 
biotechnology  would  be  valuable  (XIA  and  BUCCOLA  2005).Breakdown  of  the 
investment by technological area and other indicators of research objective would 
add even more. Unfortunately, detailed data in agricultural biotechnology are often 
either unavailable or nonexistent. 
In developing countries  plant  breeding  is  public service to support 
development  program  that  reach  near-subsistence farmers that are not likely to 
become customers of  private sector. For the most important food crops, public 
activities are at the basis of the Green Revolution and significantly contributed to 
free  distribution  of  the  half  -  bred  materials  and  finished  varieties.  The  new 
technologies may facilitate their work for poverty reduction only if they can access 
them.  
Use of the licenses for help to undeveloped countries have been used to 
make individual technologies available for research and for development. Such 
licenses are generic, rather than dealing with individual transfers, and with opening   
require explicit action and communication to facilitate actual technology transfer. 
Open-source is another model for increasing access and reducing transaction costs.  
Philosophy of innovation in networks with weak - informal - ties as opposed to a 
linear  organizational  structure  with  formal  contracts  would  underlie  an  “open 
innovation system”. Despite various initiatives to promote open source strategies 
the  models  do  not  seem  to  gain  much  importance  in  more  product  oriented K. KONSTANTINOV et al.: ETHICS IN SCIENTIFIC RESULTS APPLICATION                            199 
biotechnology  research  (SHOEMAKER  et  al.,  2001;  GRAFF  et  al.,  2002; 
http://www.cfra.org/resources/issue_brief_patenting.htm). 
A  number  of  factors  could  explain  the  unprecedented  increase  in 
applications for patents. According to HALL (2004) the initial structural break was 
largely accounted for by firms in electrical and computing technology.  In  addition,  
other  related  technological areas, such as software and  information  technology, 
witnessed a rapid  increase of  innovation and new firm creation over much  the same  
period as the increase in patents. The new  molecular and genomic tools used in 
genetically  engineering  plants  have  also  vastly  enhanced  the  enforceability  of 
intellectual  property  protection by providing  new and more powerful  means of 
establishing that someone  has  illegally used  a protected  variety. It  is now possible  
definitively characterize  plants  and  seeds at  the molecular  level by establishing 
their unique “fingerprints” in a manner similar to that used for DNA profiling in 
criminal  cases.  It  is  also  possible  to  detect  the  use  of  the  protected  varieties  or 
genetic material in breeding new varieties (KORTUM and LEMER, 1999). 
The  so-called  “farmer's  privilege”  that  allows  farmers  to  harvest  and 
legitimately use propagating material derived from the crop grown from  the original 
and  legitimately obtained  propagating  material  for subsequent cropping cycles on 
their  own  farm  should  be  a  right.  These  are  the  processes  which  maintain  and 
improve  local  biodiversity  and  adaptation  that  will  be  crucial  as  global  climate 
change arises. 
 
  
 PATENTING IN AGRICULTURAL BIOTECHNOLOGY  
The face of plant breeding research has changed significantly due to the 
rapid  technological  developments  in  the  field  of  genomics  and  to  revolutionary 
changes in the legal and policy environment in which plant scientists and breeders are 
working. 
Varieties eligible for protection are those that are new, uniform, stable (in 
the  sense  of  reproducing  their  characteristics  in  their  progeny),  and  distinct  from 
existing varieties. Principles are: (i) only the first inventor of something patentable 
can obtain a patent; (ii) the invention must be useful; (iii) the invention must be novel; 
(iv)the patent must involve a creative step.  There are different tests for the novelty.    
Different kinds of  protection  have been available for some time. Legal   
protection  of plant varieties was introduced in the United States long time  before 
development of genetically engineered plants. Since 1930 a type of patent  introduced  
especially for plants, known  as  a “plant patent,”  has  been  available  from the U.S. 
Patent and Trademark Office (USPTO) in the Department of Commerce, to protect  
novel clonally propagated (i.e., asexually reproduced) plant varieties including fruit 
trees, ornamentals, and berries.  
Plant  patents,  like  the  more  common  and  much  older  utility  patents 
available for inventions   are currently enforceable from the date they are granted until 
20 years from the date of application. Since 1970 Plant Variety Protection Certificates 
(PVPCs) have been  available from U.S. Department  of Agriculture.  The  term  of   
protection offered under PVPC is now 20 years for most crops, 25 for trees and vines. 200                                                                                   GENETIKA, Vol. 42, No. 1,195 -208, 2010 
Farmers are allowed to save seed of varieties protected by PVPCs for replanting their 
crops,  but  they  cannot  provide  or  sell  those  seeds  to  others  for  planting 
(http://www.genethics.org)   
It is important to note that plant  patents and  PVPCs  prevent only unlawful  
proliferation of the variety; they do not  prevent  the use of protected  plant  materials 
for breeding  purposes.  In  contrast,  the  more broad-ranging utility patents not only 
prevent  seed    increase  via  reproduction  of  the  same  variety,  they  also  protect 
breeders against  unauthorized  use of  protected varieties for breeding and  research  
purposes.   
Particular way of the seed production is hybridization. Seed obtained from a 
hybrid crop (produced from different male and female parental varieties) does not 
have yield as high as the initial hybrid crop. Thus, breeders of hybrid crops have an 
effective non legal protection gains replanting by farmers.  High private investment 
in the crop breeding has tended to be concentrated in hybrids, in particular hybrid of 
maize and horticultural crops. For other crops, most breeding - related research until 
recently has been largely concentrated in the public sector, in agricultural experiment 
stations and Universities (WRIGHT et al., 2005).  
The  development  of  genetic  engineering  of  plants  in  the  1980s  was 
accompanied  by  specific possibility of patentability of various  types  of  life forms, 
including  those  created  by  conventional  breeding,  and    particular  sequences  of 
genetic material or DNA such as genes, markers, and  promoters (which control  the  
expression of genes  in cells), which could be protected by utility patents. It must be 
stressed  out  that  either  positive  or  negative  effect  of  life  form  patenting  on 
humankind  and  environment  are  unpredictable.  Utility  patent  protection  is  also 
available for novel methods of breeding and genetic engineering for new varieties   
produced   by use of new methods and for research tools. Novel plant could be 
protected by a utility patent on variety or on  its  genes, by a plant patent (XIA and 
BUCCOLA, 2005; KONSTANTINOV and MLADENOVIĆ 2006, 2007, 2009).  Novel  plant  
could  also be  patented  as  a product  of  the  novel method  by which  it was 
produced, such  as genetic engineering.  Utility patents protect the plant  breeder's  or  
inventor's  rights to control  the  use,  sale,  import, and reproduction of plants that 
have been patented or that incorporate patented material. Using utility patents, plant 
breeders  can  dictate  the  terms  under  which  such  plants  can  be  used  and  could   
prevent others from using them for any subsequent breeding or for seed increase via 
replanting of the harvested seed. Many patented basic materials and methods for 
genetic engineering in agriculture were generated either in private corporations or in 
universities and are often licensed exclusively to private businesses (BOETTIGER and 
BENNETT, 2006). Biotechnology for an Open Society (http://www.bios.net/)  seeks to 
generate  open-source  development  of  suites  of  research  tools  for  biotechnology 
innovation, unhindered by any patent thickets.  
Patenting in the agricultural biotechnology differs across entity type and across 
the time. As fast as patenting grew in broadly defined agricultural biotechnology, it 
grew even faster in the modern agricultural biotechnology. In the early years of the 
records there was almost no patenting in modern agricultural biotechnology.  In the 
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period from 1980 - 1984, modern agricultural biotechnology patents averaged  about 
3%  of  all  agricultural  biotechnology  patents  (GRILLICHES,  1990).  By  1996-2000 
period patents averaged about 22% of all patents in agricultural biotechnology.  Even 
when patents obtained by modern gricultural biotechnology are extracted  from  the  
rest of the agricultural biotechnology sample, agricultural biotechnology patents still 
grew much more quickly than did total patents. What the patent data do confirm is 
the  current  importance  of  private  sector  in  commercializing  agricultural 
biotechnology,  in  particular  plant  -related  technologies  and  modern  agricultural 
biotechnology  that  relies  more  on  the application  of  molecular  biology  (XIA  and  
BUCCOLA,  2005).   
Universities may patent as a means to transfer technology to the private sector 
for  further  development,  to  attempt  to  generate  licensing  revenue,  or  perhaps  to 
contribute to the regional economic development through the scientific parks. These 
motivations for the patenting by the Universities in particular are preferable in the 
literature  rather  than  analyzed  in  any  detail  (JAFFE  and  LEMER,  2001).  Research   
publications are the alternative measure, although not strictly comparable to patents, 
because they might represent somewhat more basic research than the research that 
results in patent applications (XIA and BUCCOLA, 2005). Universities however, do not 
appear to patent the near-market technologies such as plant cultivars.  Available data 
confirm  that  the  US  government  only  tends  to  patent  in  specific  agricultural 
biotechnology  research  areas  rather  than  broadly  across  all  agricultural  areas  in 
which  it  performs  research.  This  government  patenting  appears  to  be  mainly  in 
support  of  technology  transfer what is  important  in agricultural  biotechnology  in 
terms of patent counts, but with some exceptions, their patent  portfolio mimics  the 
portfolio held by  the  private sector (HEISEY, et al. 2005). Public - sector institutions, 
that patent,  may  do  so  for  reasons  differing  from  those  motivating  private  firms 
(HENDERSON, et al., 1998;  JAFFE and  LEMER, 2001). Firms patent to protect their 
inventions, to develop strategic patent portfolios, and to generate licensing revenue 
(COHEN, et al., 2000, JAFFE, 2000). 
BUCOLA and XIA (2004) assessed the apparent decline in patent quality using 
citation based measures and proposed two hypotheses to explain this decline. First, a 
“technological  hypothesis”  proposed  that  agricultural  biotech  patents  are  moving 
downstream.  Second,  a  “strategic  hypothesis”  suggested  that  firms  are  patenting 
more to maximize the value of their patent. They determined that the evidence may 
support both the technological and strategic hypotheses. 
Several  examples  have  been  documented  of  the  struggle  to  obtain  all  the 
licenses that are necessary for introducing technologies into developing countries 
such  as  use  of  patents  resting  on  the  nutritionally  enhanced  “Golden  Rice”. 
Numerous patents in the field of agricultural biotechnology turn out to have very 
little  economic  value,  while  “Golden  Rice”  prove  to  be  extremely  valuable 
(GRILICHES, 1990). Developed at the Universities  in  Switzerland and Germany  it 
required  a  major  commercial  company  to  disentangle  the  thicket  of  rights  and 
negotiate licenses for all these patents for their use for the poor.  No agreement was 202                                                                                   GENETIKA, Vol. 42, No. 1,195 -208, 2010 
reached  because negotiations  never  started  since  patent  holders  did  not  show  an 
interest to negotiate at all (BUCCOLA and XIA, 2004).  
Patents  increasingly  reduce  the  freedom  to  operate  in  plant  breeding. 
Biotechnology  companies  are  known  to  actively  seek  patent  protection  for  their 
products. Knowledge created by the public Universities  and  research  Institutes is 
often protected   in spite of elementary human rights that  public resources should   
not be used  to enforce private rights. Patents on life and PBR (Plant Breeder s 
Right) facilitate enclosure and privatization of the global biological commons. This 
is inherently unjust and against the public interest. There are various strategies being 
used  to  study  of  Ethical  Concerns  about  Plant  Biotechnology.  In  Japan  biology 
teachers considered there was more risk from genetic engineering than the ordinary 
public (MACER, 1992; 1994a, 1994b). There is however need for the education about 
computers, pesticides, nuclear power, biotechnology and genetic engineering. Both 
benefits  and  risks  were  cited  by  many respondents.  Discovery  itself  may  not  be 
wrong, but how we use it or abuse it raises ethical questions.  
 
BIOETHICAL ISSUE OF LIFE FORM PATENTING 
Possibility to reach the balance between benefits and risk of science and   
technology depends on the level of society education of (MACER, 1990; 1992; 1994 
a,  b).    Human  population  has  not  simplified  opinion  about  the  science  and 
technology. Balancing between good and harm is indispensable  for  the  bioethical  
concern  of  the  life  and  is  indicator  of  bioethical  maturity  of  the  society.  
Comparative studies (HOBAN and KENDALL, 1992; MACER, 1995) showed  that  plant 
-plant gene  transfers  are  acceptable,  animal to animal  less, and  animal-plant or 
human-animal  gene transfers  were  least acceptable. 
The  Group  of  Advisers  on  Ethical  Aspects  of  Biotechnology  to  the 
European Commission (ECC, 1995) recommended food be labeled to indicate when 
its  composition  and  characteristics  have  been  substantially  modified  by  genetic 
engineering techniques. There is substantial equivalence between the new food and a 
traditional counterpart (e.g. virus resistant plants produced by insertion of the viral 
coat  protein,  or  herbicide  tolerant  plants  produced  by  introducing  a  protein 
comparable to one already present in a plant but tolerant to a selective herbicide). 
According to OECD (1996) investigation: (i) there is substantial equivalence between 
the new  food  and   traditional counterpart, except for  the inserted trait (e.g. insect 
protected plants produced by the insertion  of  the  Bt  gene or disease resistant plants 
produced by the introduction  of a new protein); (ii) there is substantial equivalence 
between  the  new  food  and  a  traditional  counterpart  (e.g.  virus  resistant  plants 
produced by insertion of the viral coat protein, or herbicide tolerant plants produced 
by introducing a protein comparable to one already present in a plant but tolerant to a 
selective herbicide); (iii) there is not substantial equivalence between the new food 
and a traditional counterpart (e.g. introduction of a gene or genes that encode a trait 
that significantly alters the plant for use in food or feed, such as production of a 
new oil or carbohydrate). If substantial equivalence is established they considered 
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evaluation it should be done case - by case for the product of the gene. Anyhow, 
balance  must  be  found  between  the  right  of  consumers  to  information  and  the 
imposition of unnecessary information which may confuse people over what the 
major facts relevant to their diet are (NESTLE, 1996). Each state must take responsibility 
for any risk related to deliberate release of GM
 organisms
 into the environment (Van 
WAES, 2009).
 
There are many unresolved legal and practical implications of the ethical 
issues when someone improves upon a variety that another has developed. Example 
is XA21 gene in rice. This gene is coding an important disease resistance, and 
based  on  earlier  research  by  the  International  Rice  Research  Institute  and  its 
partners in India and Mali, have been patented by the University of California, 
Davis.  After  long  negotiation  University  in  Davis  released  the  patent  for 
development  purposes  and  even  did  developed  a  benefit  share  mechanism  for 
profits derived from the commercial use of the patent (http://www.genethics.org.)  
Many  medicinal plants have been collected and selected by indigenous 
groups,  local  farmers  and  traditional  medicinal  healers.  Modern  approaches  can 
identify  the  active  ingredients  and  several  patents  have  been  issued  to  these 
companies. These are being challenged, but the issue needs further ethical resolution. 
The practical issues of royalty sharing also need to be resolved. It is quite important to 
have  international  approaches  and  support  because  food  products  are  sold  and 
transported  across  borders, and a  ban  in one  country  could be circumvented  if  a 
neighboring country approved its production (HOBAN and KENDAL, 1992).  
The issue of  Intellectual  Property  Rights (IPR)  in  public  research  could  
be  tackled  from different generic angles, including ethics - the role of science and 
academia  in  society  and  political  economy  http://www.cfra.org/resources/ 
issue_brief_patenting.htm).  
Public research organizations generally use patent protection as part of three 
strategies: maintaining their position at the frontier of science through maximizing 
their  own  freedom  to  operate,  strengthening  their  position  in  public  private 
partnerships, and obtaining a return on investment on their research through cash 
income.  
The Aims and Objectives of Plant Breeder's Rights Laws is to encourage 
plant breeders to produce  new  plant varieties, and  to benefit  society  with  access to 
new and  improved  plant varieties and assured food security.  Increased use of 
patents and the PBR, and decreased public investment in the plant breeding are 
reducing but not increasing the food and crop diversity. PBR is in many cases the 
way of the public resources privatization. Enclosing the global biological commons 
should not be permitted (GRAFF, et al., 2003a, b). It could be proposed that breeders 
be contracted by the community through governments to undertake certain essential 
work previously carried out by public sector breeders.  There are cases when PBR is 
placed on the variety hat has become available through a foreign aid  program  where 
local  breeders received  the  material  for  the  purposes  of  assisting  breeders  or 
growers in other countries. Such bio piracy should not be rewarded and exemplary 
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Strict liability should apply to gene contamination, especially where the 
pollen or seed of patented or PBR varieties transfer their genes into the genomes of 
conventional or organic crops. Plant breeders should not have  the greater rights  than  
people whose crops are contaminated  by  protected varieties. If criminal liability 
(with  penalties  of  jail  and  fines)  were  to  apply  to  alleged  infringements  of 
patents and PBR, they should  also  apply  to the inevitable contamination that   would  
ensure  from  the commercial release of (especially open-pollinated) GM and PBR  
plant varieties.   
Plant Breeders Right (PBR) law is inherently unfair since “inventiveness” is 
not a criterion for registering a plant variety under PBR. Invention is rightly a core 
criterion for a patent, which most GM companies use in preference to PBR to protect 
their varieties. Without an inventive step being required for PBR, biodiversity can 
be owned by a seed or any other company, with no innovation. This is classical 
biopiracy.  It  would  be  good  to  reward  plant  breeders  to  achieve  its  goals  - 
development of the new plant varieties to meet the challenges of predicted tough 
environmental  conditions  and  to  ensure  food  security.  Plant  breeders  have  the 
option of suing to enforce their rights if they regard them as infringed and it seems 
as sufficient remedy (MACER, 1990).     
GENE ETHICS (2007) does not accept that living organisms should be the 
subject  of monopoly  ownership  under the Patents or Plant Breeder's Rights Acts. 
Intellectual property rights should only be granted to encourage genuine inventions 
and  should  not  apply  to  organisms  originally  found  in  nature.  Plants  are  not 
inventions. PBR is doubly objectionable because, unlike patents, it does not apply 
the criteria of non-obviousness, inventiveness and reproducibility which must be 
met for the grant of a patent (http://www.genethics.org).  
Patent  Office  has  issue  as  plant  patents  under  the  Plant  Patent  Act  and   
utility patents under the Patent Act for the plants, under a Supreme Court decision 
that  confirms  the  availability  of  such  utility  patents  (J.E.M.  2001)  despite  the 
existence of more specialized statutes addressing intellectual property rights for 
specialized plants. It may be in certain cases that there are broader public policy 
reasons why it would  seem contrary to the public interest to grant patents to life forms 
( http://www.cfra.org/resources/issue_brief_patenting.htm.. ) 
Allowing patents on bacteria and seeds and the possibility of patenting their 
life forms raises  ethical  and  moral  questions  (KONSTANTINOV  and  MLADENOVIĆ 
DRINIĆ  2006).  It  also  raises  questions  relating  to  increasing  consolidation  in 
agriculture.  How  family  farmers  and  ranchers  are  treated  in  such  a  legal  and 
regulatory regime will go a long way in determining their future (Usefulness is a 
criterion for granting a U.S. patent).
  Increasing of the biological material amount 
held  privately  rather  than  in  the  public  domain  as  companies,  devote  additional 
resources  to  cost-effective  patents.  Public  plant  breeders  will  lose  access  to  the 
germplasm.  Public research  being  directed  to a greater extent toward  satisfying  the  
desires of  the firms  that  purchase  the  rights  to the patents and to a lesser extent  
toward  the desires  of farmers, ranchers and consumers.  As a consequence it  is 
greater control by firms holding patents of the crops grown from patented seed.  K. KONSTANTINOV et al.: ETHICS IN SCIENTIFIC RESULTS APPLICATION                            205 
INSTEAD OF CONCLUSION 
The patenting of life forms raises public policy issues. Social and ethical issues require 
careful analysis and debate in order to evaluate and, possibly, to reform the basis for 
the issuing life form patents.  Bioethics combines risk assessment, the concept of 
avoiding  harm,  with  an  assessment  of  benefits,  the  concept  of  doing  good  or 
beneficence. It is important to ask whether there are any new risks compared to 
traditional plant breeding. Good example  are various risks in method of genetic 
engineering (recombinant DNA technology) application and life form patenting 
with obvious consequences: (i) the risk of unintentionally changing the genes of 
an organism; (ii) the risk of harming that organism; (iii) the risk of changing the 
ecosystem in which it was involved; (iv) the risk of harming the ecosystem; (v) the 
risk of change, or harm, to any other organism of that species or others, including 
human beings (who may even be the target of change). The extent to which a change 
is judged to be a subjective harm depends on human ethical values and permanent 
consideration whether nature should be “intransient” or in some way modified. This 
relates to the facts that this technology is at least unnatural if not dangerous. 
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I z v o d 
Razvoj  novih  biotehnologija  zasnovanih  na  tehnologiji  rekombinantne  DNK, 
definisanih kao genetičko inženjerstvo, izazvao je značajne promene u načinu primene i 
komercijalizacije naučnih rezultata dobijenih u oblasti osnovnih istraživanja, posebno u 
poljoprivredi, medicini  i zaštiti životne sredine. Na hiljade patenata koji daju pravo na 
vlasništvo  nad  DNA  sekvencama/genima  je  odobreno  istraživačima  u  privatnom  i 
javnom  sektoru.  Korišćenjem  patentiranih  gena,  koji  kontrolišu  važne  osobine 
(otpornost prema bolestima na pr.)  stvorene su i uvedene u proizvodnju nove sorte i 
hibridi najznačajnijih gajenih biljnih vrsta kao što su kukuruz, soja, pirinač kao i mnoge 
ukrasne biljke. Istraživači koji su vlasnici patenta gena imaju pravo na patentnu zaštitu i 
transgenih  biljaka  koje  poseduju  taj  gen.  Od  posebnog  značaja  za  istraživače  u 
poljoprivredi, posebno u oblasti genetike i oplemenjivanja je mogućnost, korišćenjem 
genskih proba, karakterizacije genotipova  i dobijanje pouzdanih podataka o genetičkoj 
varijabilnosti , naročito u korišćenju kako u sopstvenim programima tako i u razmeni 
biološkog materijala sa drugim kolekcijama. Slobodna dostupnost tih proba je jedan od 
preduslova. Pitanje opravdanosti patentiranja sekvenci DNA/gena i njihovog korišćenja 
je  neophodno  ponovo  otvoriti  jer  su  patenti  u  nekom  slučaju  opravdani  a  unekom 
moraju  da  budu  oprezno  razmatrani..    Patentno  pravo  na  sekvencu  DNA/gen  kao 
eksperimentalni  material  nije  opravdano  i  treba  ga  obeshrabrivati.  Najbolji  način  za 
ograničavanje zloupotrebe je strogo primena kriterijuma za patentiranje, posebno za 
pravo korišćenja patenata. Mnogo pravedniji, na etičkim principima zasnovan sistem 
proizvodnje hrane mora da ima ugrađena tri globalna cilja: poboljšanje kvaliteta života, 
zaštitu životne sredine i obezbeđenje zdravlja populacije sa akcentom na korišćenje 
hrane proizvedene od GMO. Jedan od pristupa ostvarenju ovih ciljeva je etičko i istinito 
obeležavanje hrane od GMO, jer potrošači imaju pravo izbora da li žele da koriste 
genetički modifikovanu hranu ili ne. Interesantan je primer i rizici koji proizilaze iz 
neograničene  dostupnosti  i  korišćenja  genetičkih  resursa,  njihova  transformacija 
korišćenjem  genetičkog  inženjerstva,  patentiranje  “novog”  genotipa  –  organizma  a 
zatim njegova prodaja vlasniku korišćenog originalnog genotipa. Društvo ima obavezu 
podizanja nivoa kvaliteta hrane I standard življenja uz puno poštovanje etika na svakom 
stepenu razvoja. U radu su navedeni neki od slučajeva patentiranja koji ne zadovoljavaju 
osnovne etičke norme. 
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